Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925127 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 994
- Enrollment target
NCT05925127 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 994 participants.
The verdict
NCT05925127, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 994 participants
- Enrollment target
Study Summary
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 \[prototype Wuhan vaccine with Matrix-M adjuvant\] or NVX-CoV2601 \[Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant\]).
Interventions
- BIOLOGICAL NVX-CoV2373 (5μg)
- BIOLOGICAL NVX-CoV2601 (5μg)
- BIOLOGICAL NVX-CoV2601(5μg)
- BIOLOGICAL NVX-CoV2601 (35μg)
- BIOLOGICAL NVX-CoV2601(35μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 994 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05925127
The ClinicalTrials.gov registry entry for NCT05925127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 994 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NVX-CoV2373 (5μg) is the first listed.
NCT05925127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05925127 about?
NCT05925127 is a clinical study titled "Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines". This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvan...
What is the current status of trial NCT05925127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 994 participants. The study started on 2023-10-16. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT05925127?
The interventions under investigation include: NVX-CoV2373 (5μg) (BIOLOGICAL), NVX-CoV2601 (5μg) (BIOLOGICAL), NVX-CoV2601(5μg) (BIOLOGICAL), NVX-CoV2601 (35μg) (BIOLOGICAL), NVX-CoV2601(35μg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05925127?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.